Clinical Trial: The Clinical Efficacy of DFPP in Patients With AAGN

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: A Prospective, Controlled Study of Double Filtration Plasmapheresis (DFPP) in Patients With Antineutrophil Cytoplasmic Autoantibody Associated Glomerulonephritis (AAGN)

Brief Summary: The clinical efficacy of double filtration plasmapheresis(DFPP) in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).

Detailed Summary: This is a single center, prospective, randomized,controlled study to compare the clinical efficacy of double filtration plasmapheresis (DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy versus IV-CTX pulse therapy in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).
Sponsor: Zhi-Hong Liu, M.D.

Current Primary Outcome: the renal recovery rate [ Time Frame: 3 months ]

the renal recovery rate at 3 mo defined by dialysis independence and the SCr <5mg/dl for the patients needed renal replacement therapy at the basement, or the SCr decreased more than 30% of the baseline and the urine sediment red blood cell less than 50*104/ml for the patients without renal replacement at the basement.


Original Primary Outcome: Same as current

Current Secondary Outcome: kidney survival [ Time Frame: 12 months ]

patient and kidney survival at 12 month


Original Secondary Outcome: Same as current

Information By: Nanjing University School of Medicine

Dates:
Date Received: June 3, 2014
Date Started: June 2014
Date Completion: November 2018
Last Updated: May 14, 2017
Last Verified: May 2017